Breaking News

Netherlands Has 3-0 Lead Over Brazil in World Cup Game
Tweet TWEET

Terumo Interventional Systems Launches The Detachable AZUR® CX Peripheral Coil System

Terumo Interventional Systems Launches The Detachable AZUR® CX Peripheral Coil
                                    System

The First & Only Peripheral Coil Designed for Cross-Sectional Coverage
Incorporating the Benefits of Terumo® Patented Hydrogel Technology

PR Newswire

SOMERSET, N.J., Oct. 8, 2013

SOMERSET, N.J., Oct. 8, 2013 /PRNewswire/ -- Terumo Interventional Systems, a
division of Terumo Medical Corporation, today announced the nationwide
availability of the AZUR^® CX Peripheral Coil System (AZUR CX), the first and
only peripheral embolization coil designed to provide cross-sectional coverage
incorporating the benefits of Terumo's patented hydrogel technology. Terumo
launched the AZUR CX at the 11^th Vascular InterVentional Advances Conference
(VIVA), October 8 to 11, in Las Vegas, NV.

The AZUR CX is an expansion of Terumo's AZUR^® family of embolization coils
for endovascular occlusion of peripheral vessels. It has a unique coil
construction with hydrogel on the inside for a soft, flexible design. The
hydrogel technology creates a scaffold for neointimal growth formation and
allows mechanical occlusion of the vessel with less reliance on thrombus for
embolization. The AZUR CX creates a complex shape that enhances
cross-sectional coverage by filling the vessel, leaving no gap in the center.
It can be deployed with minimal catheter manipulation.

"Placing embolic coils in high-flow vessels is always a challenge, because of
the possibility the coil will move after placement. Maintaining control is
critical. From the first loop, theAZURCXwith hydrogel technology instills
confidence, because it creates a stable anchor in the vessel,"said Frank R.
Arko III, MD, Sanger Heart and Vascular Institute, Carolinas Medical Center,
Charlotte, North Carolina. "The coil has minimal preparation time and with the
AZUR® Detachment Controller I can achieve precise placement."

The U.S. market for peripheral vascular embolization coil procedures is
expected to grow by approximately 5.8 percent annually through 2016^1. This
increase is primarily driven by innovation in detachable coil technology and
access devices, which allow physicians to treat a wider variety of patient
conditions. Compared to traditional pushable embolic coils, detachable coils
offer enhanced clinical benefits, including more precise positioning, that
allow physicians to extend further into more tortuous anatomy, where distal
embolization is a concern.

"The AZUR CX is a great addition to Terumo's diversified portfolio of
peripheral embolization products. This device is yet another example of
Terumo's commitment to satisfying the needs of physicians who treat patients
in the emerging embolization market," said Chris Pearson, Vice President,
Marketing, Terumo Interventional Systems. "Terumo's mission is to combine the
right product solutions with high-quality training and education programs that
help physicians deliver the highest level of clinical care."

For more information about the AZUR CX, visit www.terumois.com or connect to
your local Terumo sales representative by calling 800-862-4143.

^1Total PV Embolization Procedures, by Indication, US, 2009-2016. Millennium
Research: Combines Pushable & Detachable MKT

Terumo Interventional Systems
Terumo Interventional Systems (TIS), a division of Terumo Medical Corporation,
is a market leader in minimally invasive entry site management and lesion
access technologies. TIS offers a complete, solution-based product portfolio
used in advanced coronary, peripheral endovascular and urological treatments
with strategic initiatives in Transradial Access, Complex Coronary
Intervention and Critical Limb Ischemia. TIS combines innovative research and
development with a deep market understanding to create a pipeline of industry
leading devices that deliver clinical value, economic benefit, and enhanced
patient outcomes. Terumo Medical Corporation is part of Tokyo-based Terumo
Corporation; one of the world's leading medical device manufacturers with $4
billion in sales and operations in more than 160 nations.

SOURCE Terumo Interventional Systems

Website: http://www.terumois.com
Contact: Robert Murphy, Jitsu Public Relations, Inc., (908) 276-0777,
rmurphy@jitsuPR.com